Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
Status:
Completed
Trial end date:
2017-10-04
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, crossover study
that will evaluate the efficacy of LUM/IVA in subjects with CF 12 years of age and older who
have at least one A455E mutation.